A 68-Year-Old Woman with ALK+ Non–Small Cell Lung Cancer

home / case-based-peer-perspectives / a-68-year-old-woman-with-alk-non-small-cell-lung-cancer

Karen Reckamp, MD, comments on the management and treatment of a 68-year-old woman with ALK+ NSCLC, as well as data demonstrated in the ALTA-1L trial, use of brigatinib, and her own clinical experiences.